A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

Summary

This local Phase 3 study is planned to confirm the efficacy and safety in Japanese PAH participants. The primary population of this study is Japanese PAH participants with World Health Organization Functional Class (WHO FC) II or III while the study includes PAH participants with WHO FC I or IV as other populations. There are no hypotheses for this study.

Timeline

Start

2023-05-10

Primary completion

2024-03-12

Completion

2025-11-06

Publications

• Results Matsubara H, Tanabe N, Ogo T, Abe K, Inami T, Maeda Y, Arano I, Shirakawa M, Sakai R, Cornell AG; Sotatercept Study 020 Investigators. Phase 3, Open-Label Multicenter Study of Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension. JACC Asia. 2026 Mar;6(3):297-309. doi: 10.1016/j.jacasi.2025.12.009. Epub 2026 Jan 31.

Drugs

Indications